GSK3B and early-onset autosomal dominant Alzheimer disease: The results reported here are indicative of the effects of increased GSK3β levels and, to some extent, they may have implications when considering the potential side effects and the potential therapeutic efficacy of chronic administration of potent and selective GSK-3 inhibitors that are currently under development for treatment of chronic conditions such as Alzheimer's disease and mood disorders [13], [14].